Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Ashley E. Rosko, MD, Sarah A Wall, MD, Robert A Baiocchi, MD PhD, Don M. Benson, Jr., MD PhD, Jonathan E. Brammer, MD, John C. Byrd, MD, Yvonne A. Efebera, MD MPH, Kami J. Maddocks, MD, Kerry A. Rogers, MD, Carolyn Presley, MD, Desiree Jones, Ying Huang, MS, MA, Michelle Naughton, PhD MPH

Blood (2019) 134 (Supplement_1): 4776.

https://doi.org/10.1182/blood-2019-130531

Published: 2019

Journal Articles

An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)

DR. Brian Koffman, John M. Pagel, MD PhD DSc, Andy Kaempf, Byung Park, PhD, Liza Avruch, Christopher Lee, PhD MS, Babak Movassaghi, PhD MBA, John C. Byrd, MD, Alan Skarbnik, MD, Matthew S. Davids, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4716.

https://doi.org/10.1182/blood-2019-123579

Published: 2019

Journal Articles

The Effects of Utilization of Individualized Pain Plans in Treatment of Vaso-Occlusive Crises in the Emergency Department

Sherraine Griffin, MD, Payal Desai, MD, Eric Adkins, MD MSc, Michael G (MD) Purcell, MD, Luca Delatore, MD, Ying Huang, MS, MA, Melanie Heinlein, BSc

Blood (2019) 134 (Supplement_1): 4682.

https://doi.org/10.1182/blood-2019-126991

Published: 2019

Journal Articles

Characterization of Community-Based Socioeconomic Factors, Utilization, and Adherence in Children with Sickle Cell Disease

Ronay Thomas, BS, Patrick T. McGann, MD, Andrew Beck, MD MPH, Amanda Pfeiffer, Kyesha M James, BS

Blood (2019) 134 (Supplement_1): 4686.

https://doi.org/10.1182/blood-2019-130637

Published: 2019

Journal Articles

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Christopher J. Walker, PhD, Ann-Kathrin Eisfeld, MD, Hatice G Ozer, PhD, Jessica Kohlschmidt, PhD, Deedra Nicolet, Krzysztof Mrózek, MD PhD, Dimitrios Papaioannou, MD, Luke K Genutis, BS, Bayard L Powell, MD, Geoffrey L. Uy, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard Stone, MD, Ramiro Garzon, MD, John C. Byrd, MD, Albert de la Chapelle, MD PhD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 1247.

https://doi.org/10.1182/blood-2019-127478

Published: 2019

Journal Articles

Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study

Deirdra Terrell, PhD, Spero Cataland, MD, Laura Beebe, PhD, San Keller, PhD MS, Julie Panepinto, MDMSPH, Sara K. Vesely, PhD MPH, James George, MD, Rachel Ann Kelley, BS, Marshall Cheney, PhD

Blood (2019) 134 (Supplement_1): 931.

https://doi.org/10.1182/blood-2019-128989

Published: 2019

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

Journal Articles

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1049.

https://doi.org/10.1182/blood-2019-125417

Published: 2019

Journal Articles

Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Camila Masias, MDMPH, Krista Carter, Haiwa Wu, Shangbin Yang, PhD, Alcinda Flowers, MD, Spero Cataland, MD

Blood (2019) 134 (Supplement_1): 1098.

https://doi.org/10.1182/blood-2019-130561

Published: 2019

Journal Articles

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Kellie J Archer, PhD, Allison Walker, Krzysztof Mrózek, MD PhD, Andrew J. Carroll, PhD, Jessica Kohlschmidt, PhD, Ann-Kathrin Eisfeld, MD, Marius Bill, MD PhD, Christopher J. Walker, PhD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard Stone, MD, John C. Byrd, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2694.

https://doi.org/10.1182/blood-2019-125727

Published: 2019

Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey

Blood (2019) 134 (Supplement_1): 2571.

https://doi.org/10.1182/blood-2019-128872

Published: 2019

Journal Articles

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

Janani Ravikrishnan, Tzung-Huei Lai, PhD DVM, Elizabeth Muhowski, Lindsey Brinton, PhD, Katie Williams, MS, Alexandria Thompson, James S. Blachly, MD, Hatice Gulcin Ozer, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer Woyach, MD, Deepa Sampath, PhD

Blood (2019) 134 (Supplement_1): 2526.

https://doi.org/10.1182/blood-2019-128574

Published: 2019

Journal Articles

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

Ann-Kathrin Eisfeld, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MD PhD, Deedra Nicolet, MS, Alice S. Mims, MD, Dimitrios Papaioannou, MD, Christopher J. Walker, PhD, James S. Blachly, MD, Sophia E. Maharry, Andrew J. Carroll, PhD, Richard M. Stone, MD, Bayard L Powell, MD, Albert de la Chapelle, MD PhD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, John C. Byrd, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2681.

https://doi.org/10.1182/blood-2019-130076

Published: 2019

Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD

Blood (2019) 134 (Supplement_1): 3045.

https://doi.org/10.1182/blood-2019-124538

Published: 2019

Journal Articles

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Kerry A Rogers, MD, Lai Wei, PhD, Seema A. Bhat, MD, Dan Jones, MD PhD, Erlene K. Seymour, MD, Deborah M. Stephens, DO, J Christine Ye, MDMSc, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 3049.

https://doi.org/10.1182/blood-2019-125360

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3050.

https://doi.org/10.1182/blood-2019-125411

Published: 2019

Journal Articles

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Francesca Cottini, MD, Nita Williams, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS, MSc, Maria Chaudhry, MD, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD

Blood (2019) 134 (Supplement_1): 5501.

https://doi.org/10.1182/blood-2019-129128

Published: 2019

Journal Articles

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

Jennifer Woyach, MD, Deborah M. Stephens, DO, Ian W. Flinn, MD PhD, Seema A. Bhat, MD, Ronald E. Savage, Feng Chai, MD, Sudharshan Eathiraj, PhD, Lindsey Granlund, Lyndsey A. Szuszkiewicz, Brian Schwartz, MD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4298.

https://doi.org/10.1182/blood-2019-127260

Published: 2019

Journal Articles

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Michael Ozga, MD, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Patrick Elder, MS, Nita Williams, Naresh Bumma, MD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Rami Kahwash, MD, Ajay Vallakati, MD, Courtney Campbell, MD PhD, Samir Parikh, MD, Salem Almaani, MD, Jason Prosek, MD, Elyse Redder, PT, CLT-LANA, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 1833.

https://doi.org/10.1182/blood-2019-124206

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)

The Effects of Utilization of Individualized Pain Plans in Treatment of Vaso-Occlusive Crises in the Emergency Department

Characterization of Community-Based Socioeconomic Factors, Utilization, and Adherence in Children with Sickle Cell Disease

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma

Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies

The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only